New research has detailed each type of cancer mutation that causes drug resistance, helping to uncover targets for drug development and identify potential effective second-line therapies. In a new large-scale study, researchers from the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), Open Targets, and collaborators… Read More
DDW’s Megan Thomas speaks with Dr Chantale Bernatchez, Director of Cell Therapy Process Development at CTMC, about tumour infiltrating lymphocyte (TIL) therapy and what's on the horizon for this new class of cell therapy. TIL therapy is a form of cancer immunotherapy. It's an autologous cell therapy, meaning cells are… Read More
Etcembly has launched a new research study aiming to uncover new targets for cancer therapies by analysing the immune cells of cancer survivors. The ETCh study is recruiting people aged 18-65 who are living with or have survived cancer to join the study, as well as… Read More
This Breast Cancer Awareness Month, Diana Spencer takes a look at the current situation and the new therapies on the horizon. Breast cancer is the most common cancer globally, with around 2.3 million new cases every year, according to data from the World Health Organization (WHO). It represents one in… Read More
DDW’s Megan Thomas interviews Dr Oren Gilad, President and CEO of Aprea Therapeutics, about the company’s targeted therapeutics that overcome the traditional issues associated with chemotherapy such as toxicity and tumour resistance. MT: Can you provide an overview of Aprea Therapeutics’ approach to developing new cancer therapies and how it… Read More
TechBio Recursion will be launching a Phase I/II clinical trial of REC-1245 for the treatment of biomarker-enriched solid tumours and lymphoma, following the go-ahead from the US Food and Drug Administration (FDA). REC-1245 is a potent and selective RBM39 degrader with a potential first-in-class profile. Recursion identified the novel regulatory… Read More
Significant changes in the molecular characteristics of tumour samples occur within as little as 10 minutes after surgical removal, a new study led by Indivumed Therapeutics has revealed. The findings underline the importance of rapid snap freezing of tissue samples to reliably capture cancer biology and… Read More
A team of UK universities, hospitals and industry, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust, have launched a new platform to understand immunotherapy response and side effects in cancer. The programme will be funded by £9 ($11.7) million from the… Read More
Researchers at the University of Oxford in the UK have been awarded up to £600,000 ($786,525) from Cancer Research UK to create the world’s first vaccine to prevent ovarian cancer. OvarianVax is a vaccine that will teach the immune system to recognise and attack the earliest… Read More
A new study in mice by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) in New York has identified a promising drug combination for the treatment of muscle-invasive bladder cancer. Rosiglitazone plus trametinib worked synergistically to not only induce tumour cell death, but also shift… Read More
Imperial College spin-out company NK:IO has completed a seed round to a total of £5.9 ($7.8) million. The round included additional funding from UK Innovation Science and Seed Fund (UKI2S), managed by Future Planet Capital, Cambridge Angels and Cancer Research Horizons. The company says the funds will be used to… Read More
Investigators saw a 91% overall response rate (ORR) in patients with relapsed/refractory multiple myeloma (RRMM) following treatment with allogeneic CAR-T therapy P-BCMA-ALLO1 and lymphodepletion. The interim data from an ongoing Phase I trial in patients who have previously received three or more prior lines of therapy… Read More
Experts from Cancer Research UK Children’s Brain Tumour Centre of Excellence in Cambridge, UK are set to share around £3.2 ($4.2) million to find and test better and less toxic ways to treat children’s brain tumours. The funding announcement comes during Childhood Cancer Awareness Month. Read More
Cancer immunotherapy has set new standards in cancer care, but many patients are still not responding. RNA modifying enzymes (RME) research could be a way to improve results. DDW’s Megan Thomas reflects on STORM Therapeutics’ approach for the future of this mechanism of action. Turning points and catalysts March 2011… Read More
Scientists have pinpointed thousands of genetic changes in a gene that may increase a person’s risk of developing breast and ovarian cancer and also identified new potential therapeutic targets. Researchers from the Wellcome Sanger Institute and their collaborators focused on the ‘cancer protection’ gene RAD51C, known… Read More
Scientists have discovered that a protein linked to prostate cancer is associated with more aggressive disease and could be a new target for treatment. The team at The Institute of Cancer Research, London, UK, have shown that the BCL2 protein was abundant in a subtype of… Read More
